Prestige Consumer Healthcare Inc. (NYSE:PBH) reported fiscal third-quarter results on Thursday showing revenue that exceeded analyst expectations, while earnings matched forecasts as the company continues addressing supply chain constraints.
The company’s shares rose about 0.7% in after-hours trading following the earnings release.
Prestige posted revenue of $283.4 million for the quarter ended December 31, 2025, beating analyst estimates of $281.12 million, although revenue declined 2.4% from $290.3 million recorded in the same period a year earlier. Adjusted earnings per share were $1.14, in line with analyst projections but below the $1.22 reported in the prior-year quarter.
The decline in revenue was largely driven by weaker sales in the Ear & Eye Care segment, primarily due to supply limitations affecting the company’s Clear Eyes product line. The company noted that supply conditions showed sequential improvement during the quarter. Despite the challenges, quarterly revenue exceeded the company’s earlier internal guidance.
“We exceeded our third quarter revenue outlook and delivered solid profitability in the quarter, which reflected the benefits of our diverse business model and strong financial profile,” said Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare.
During the quarter, Prestige completed its acquisition of eye care manufacturer Pillar5 Pharma, Inc., which the company expects will help alleviate supply shortages affecting Clear Eyes products. Prestige also repurchased approximately 0.8 million shares during the period at a total cost of $45.8 million.
For fiscal 2026, the company narrowed its revenue outlook to approximately $1.1 billion, compared with its previous forecast range of $1.1 billion to $1.15 billion. The updated guidance is slightly below analyst consensus expectations of $1.11 billion. Prestige also revised its full-year earnings outlook, projecting earnings per share of around $4.54, compared with analyst estimates of $4.56.
“Looking ahead we continue to rebuild our supply chain capacity for Clear Eyes and expect supply improvements in coming quarters to support long-term demand,” Lombardi added. “We are narrowing our fiscal 2026 net sales outlook to approximately $1.1 billion to reflect a continued challenging consumer environment.”
The company maintained its free cash flow forecast of at least $245 million for fiscal 2026, underscoring its strong financial position despite ongoing market headwinds.